The immunogenicity of therapeutic proteins and the fabry antibody standardization initiative

Clinical Therapeutics

Volumn 30, Issue SUPPL. 2, 2008, Pages

  Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTIBODY; ANTISERUM; ASPARAGINASE; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; ENZYME ANTIBODY; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE; INSULIN; INTERFERON; INTERLEUKIN 2; MEGAKARYOCYTE DERIVED GROWTH FACTOR; PROTEIN DERIVATIVE; RECOMBINANT DNA; STREPTOKINASE; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; FABRY DISEASE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIPIDOSIS; MULTIPLE SCLEROSIS; QUALITY CONTROL; STANDARDIZATION; THROMBOCYTOPENIA;

ANTIBODIES; FABRY DISEASE; HUMANS; IMMUNE TOLERANCE; PROTEINS; REFERENCE STANDARDS;

EID: 41449087436     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80041-0     Document Type: Article

References (6)

1. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 1 (2002) 457-462
2. Lee C., and Lillicrap D. Astermark J. Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors. Semin Thromb Hemost 32 Suppl 2 (2006) 10-24
3. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther. 24 (2002) 1720-1740
4. Hermeling S., Crommelin D., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21 (2004) 897-903
5. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
6. Schellekens H. Casadevall N. Immunogenicity of biopharmaceuticals. The European perspective. Dev Biol (Basel) 112 (2003) 23-28